Article

COA and ASCO Issue Joint Statement on Oncology Payment Reform

COA and ASCO are issuing a joint statement on payment reform in cancer care. The goal is to improve the lives of individuals with cancer, in part by developing and supporting payment systems based on evidence-based medicine and measures of quality and value in cancer care.

COA and ASCO are issuing a joint statement on payment reform in cancer care. The statement results from collaboration between the two organizations, in concert with AmerisourceBergen/ION and McKesson/US Oncology, to arrive at principles to guide the evolution of health care payment systems that support high-quality, high-value cancer care. The goal is to improve the lives of individuals with cancer, in part by developing and supporting payment systems based on evidence-based medicine and measures of quality and value in cancer care.

Read the full story here: http://bit.ly/1eexzCn

Source: Community Oncology Alliance

Related Videos
Nini Wu, MD, Navista
Constance Blunt, MD, medical oncologist, Mary Bird Perkins Cancer Center
Lalan Wilfong, MD
Katherine Baker, MD, MMHC
Nini Wu, MD, MBA
Mike Fazio, Navista, Cardinal Health
Andrew Chapman, DO
Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center
Laura Bobolts, PharmD, BCOP, senior vice president of clinical strategy and growth at OncoHealth
Related Content
AJMC Q&A with Eileen Peng, PharmD | Background image credit: ipopba - stock.adobe.com
May 21st 2025

The Role of Pharmacists Expands Beyond Dispensing for Novel Cancer Therapies: Eileen Peng, PharmD

Laura Joszt, MA Eileen Peng, PharmD
The advent of novel cancer care therapies such as chimeric antigen receptor T-cell therapy and bispecific antibodies is transforming the role of pharmacists in enhancing patient care.
AJMC Managed Care Cast
December 31st 2024

AJMC® Editors Reflect on 2024 and Look Forward to a Milestone

Christina Mattina
The editors in chief of The American Journal of Managed Care® discuss the key managed care research and news from 2024 and look forward to the journal’s upcoming 30th anniversary.
FDA Approved | Image credit: chrisdorney – stock.adobe.com
May 14th 2025

Teliso-V Approved to Treat Advanced NSCLC With High c-Met Protein Overexpression

Hayden E. Klein
Telisotuzumab vedotin (Teliso-V) gained FDA approval as a targeted therapy for patients with advanced non–small cell lung cancer (NSCLC) with high c-Met overexpression, offering new hope.
managed care cast logo
October 24th 2024

Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions

Brooke McCormick
On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Jack & Sheryl Morris Cancer Center | Image credit: RWJBarnabas Health
May 14th 2025

New Jersey’s First Freestanding Cancer Hospital Opens in New Brunswick

Pearl Steinzor
RWJBarnabas Health and Rutgers Cancer Institute unveil the Jack & Sheryl Morris Cancer Center—1 of only 13 freestanding cancer hospitals in the US.
At 3 months, hospitalizations among patients enrolled in RSM were 19% lower vs historical controls. | Image Credit: Nuttapong punna - stock.adobe.com
May 14th 2025

Remote Symptom Monitoring Linked to Reduced Hospitalization Risk for Patients With Cancer

Rose McNulty
Remote symptom monitoring in cancer care reduces hospitalizations, enhances value-based care, and supports diverse patient populations, according to new findings.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo